This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Pluristem To Present At FDA Symposium

Stocks in this article: PSTI

HAIFA, Israel, May 29, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the company has been invited to present at the U.S. Food & Drug Administration's (FDA) Medical Countermeasures initiative (MCMi) which is sponsoring its 2nd annual Regulatory Science Symposium on May 29-31, 2013 at FDA headquarters in Silver Spring, Maryland.

The FDA's Office of Counterterrorism and Emerging Threats, Medical Countermeasures Initiative, invited Pluristem to present at this symposium. William R. Prather RPh, MD, Pluristem's Senior Vice President Corporate Development, will present Pluristem's patented PLX (PLacental eXpanded) cell technology and its potential use in the treatment of the complications arising from the acute radiation syndrome (ARS). The data presented by Dr. Prather include preliminary preclinical information on the radio-mitigating activity of intramuscularly administered PLX-RAD cells generated in collaboration with Professor Raphael Gorodetsky and his team at the Biotechnology and Radiobiology Laboratory at the Sharett Institute of Oncology at Hadassah Medical Center, Hadassit,Hadassah Medical Organization (HMO), Jerusalem, the National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, and the Berlin Bradenburg Center for Regenerative Therapies (BCRT), Charite University, Berlin.  

Zami Aberman, Pluristem's Chairman and CEO, stated, "We are proud to be invited to present data on the use of our PLX cells to mitigate the harmful effects sustained from acute radiation injury. This presentation is a supplement to the work currently being performed by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the U.S. National Institutes of Health (NIH), to evaluate our PLX cells in animal models of ARS."

  About Acute Radiation Syndrome (ARS)

ARS represents a constellation of signs and symptoms that occur between several minutes and several weeks after exposure to high doses of ionizing radiation and affecting multiple organs such as the hematological and gastrointestinal systems. The hematological syndrome follows radiation damage to the bone marrow and is characterized by severe decreases in red blood cells, white blood cells and platelets that predispose afflicted individuals to infection, bleeding and potential death.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,380.41 +263.17 1.63%
S&P 500 1,886.76 +24.00 1.29%
NASDAQ 4,258.4380 +41.0480 0.97%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs